POLYMORPHISMS OF DRUG TRANSPORTERS AND CLINICAL RELEVANCE - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 662

C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int J
Oncol 23:509-517.
192. Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, Weissbrich B.
2003. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma lev-
els of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res 8:531-
534.
193. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano
L, Locatelli A, Verweij J, Sparreboom A, McLeod HL. 2005. Association of CYP2C8,
CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Clin Cancer Res 11:8097-8104.
194. Humeny A, Rodel F, Rodel C, Sauer R, F uzesi L, Becker C, Efferth T. 2003. MDR1 single-
nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinomas
detected by MALDI-TOF mass spectrometry. Anticancer Res 23:2735-2740.
195. Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R, Deissler H. 2003.
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemother-
apy in locally advanced breast cancer. Int J Oncol 22:1117-1121.
196. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz
P, Burk O, Decker J, Alken P, et al. 2002. Association of the P-glycoprotein transporter
MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am
Soc Nephrol 13:1847-1854.
197. van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, van der Holt B, Vossebeld PJ,
Pieters R, Sonneveld P. 2001. MDR1 gene-related clonal selection and P-glycoprotein
function and expression in relapsed or refractory acute myeloid leukemia. Blood 97:3605-
3611.
198. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y,
Higuchi S, Otsubo K. 2002. Role of human MDR1 gene polymorphism in bioavailability
and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72:209-
219.
199. Kim DH, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB, Kim JG, Suh JS, Do YR, Lee KB.
2006. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes
in de novo acute myeloid leukemia. Int J Cancer 118:2195-2201.
200. Plasschaert SL, Groninger E, Boezen M, Kema I, de Vries EG, Uges D, Veerman AJ,
Kamps WA, Vellenga E, de Graaf SS, de Bont ES. 2004. Influence of functional poly-
morphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lym-
phoblastic leukemia. Clin Pharmacol Ther 76:220-229.
201. Bleiber G, May M, Suarez C, Martinez R, Marzolini C, Egger M, Telenti A. 2004. MDR1
genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease
progression before treatment. J Infect Dis 189:583-586.
202. Zhu D, Taguchi-Nakamura H, Goto M, Odawara T, Nakamura T, Yamada H, Kotaki H,
Sugiura W, Iwamoto A, Kitamura Y. 2004. Influence of single-nucleotide polymorphisms
in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical
implication for highly active antiretroviral therapy. Antivir Ther 9:929-935.
203. Wong M, Evans S, Rivory LP, Hoskins JM, Mann GJ, Farlow D, Clarke CL, Balleine
RL, Gurney H. 2005. Hepatic technetium Tc 99 m-labeled sestamibi elimination rate and
ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients
with cancer. Clin Pharmacol Ther 77:33-42.